Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Exclusion Criteria

• •1. Histopathologically confirmed small cell carcinoma components.
• •2. Presence of multiple pulmonary nodules.
• •3. Incomplete resections (R1/R2) or resections via bilateral lobectomy, pneumonectomy, or wedge resection.
• •4. A history of any systemic anti-tumor treatment, including but not limited to surgery, neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
• •5. Significant allergies to any targeted drugs, immunotherapies, or chemotherapy agents used in the study.
• •6. Previous use of any traditional Chinese medicine with anti-tumor properties, or use of such medicine within 2 weeks prior to surgery.
• •7. History of other malignancies within the past 5 years, with the exception of the following:
• •* Other malignancies fully cured by surgery with a disease-free survival of more than 10 years
• •* Curable basal cell carcinoma of the skin
• •* Bladder carcinoma in situ
• •* Cervical carcinoma in situ
• •8. History of interstitial lung disease, drug-induced interstitial lung disease, radiation-induced pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease.
• •9. Active hepatitis B, defined as HBsAg positive with an HBV-DNA copy number exceeding the ULN established by the study center, accompanied by abnormal liver function, or requiring treatment as evaluated by the investigator.
• •10. Presence of any unstable systemic disease, including but not limited to active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the past 3 months, serious arrhythmias that requires medication, liver disease, kidney disease, or metabolic disorders.
• •11. Evidence of any other diseases, neurological or metabolic disorders, or physical exam or laboratory findings that may suggest contraindications for the investigational drug, or a high risk for treatment-related complications.
• •12. Any of the following cardiac conditions:
• •* Resting ECG QT interval (QTc) \> 470 msec.
• •* Significant abnormalities in rhythm, conduction, or morphology on resting ECG, including complete left bundle branch block, third-degree atrioventricular block, or second-degree atrioventricular block
• •* Factors increasing the risk of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under the age of 40, or use of medications known to prolong QT interval.
• •13. Blood transfusion within 2 weeks prior to and during the surgery.
• •14. History of alcohol or drug abuse.
• •15. Pregnant or breastfeeding females.
• •16. Any other factors that the investigator deems may affect the progress of the study or compromise the trial data